CD16 and CD56 are key surface markers used to identify Natural Killer (NK) cells, which play a crucial role in innate immunity by targeting virus-infected cells and tumors.
NK cells are broadly classified into two major subpopulations:
| NK Cell Subset | CD16 Expression | CD56 Expression | Function |
|---|---|---|---|
| CD56^bright CD16⁻ | Low/absent | High | Cytokine production (IFN-γ, TNF-α), immune regulation |
| CD56^dim CD16⁺ | High | Low | Cytotoxic activity (killing of infected/tumor cells) |
CD56^bright CD16⁻ NK cells: Primarily found in lymphoid tissues, involved in cytokine secretion, immune modulation.
CD56^dim CD16⁺ NK cells: Predominant in peripheral blood (~90% of NK cells), responsible for direct cytotoxic activity via perforin and granzyme release.
✅ Primary Immunodeficiencies
Classical NK Cell Deficiency (CNKD): Genetic defects in NK cell development
Functional NK Cell Deficiency (FNKD): Normal NK count but impaired function
✅ Viral Infections
Chronic HIV, CMV, Epstein-Barr Virus (EBV), Hepatitis B/C → Decreased NK function
Severe COVID-19 → NK cell exhaustion
✅ Cancer & Hematologic Disorders
Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL) → Reduced NK cell function
Multiple Myeloma (MM) → Defective NK cytotoxicity
✅ Autoimmune Disorders
Systemic Lupus Erythematosus (SLE) → Reduced NK cells contribute to immune dysregulation
✅ Viral Infections (Acute Phase)
Early response to viral infections (influenza, CMV, EBV, COVID-19) leads to NK expansion
✅ Chronic Inflammatory Conditions
Rheumatoid Arthritis (RA), Psoriasis → Increased NK cell activation
✅ NK Cell Leukemia/Lymphoma
Aggressive NK Cell Leukemia (ANKL) → Uncontrolled proliferation of CD16+CD56+ NK cells
Extranodal NK/T-Cell Lymphoma (ENKTL) → Strong CD56 expression
Method: Flow Cytometry
Sample Type: Peripheral blood
Reported as:
NK cell percentage of total lymphocytes (%)
Absolute NK cell count (cells/µL)
CD16+CD56+ and CD56^bright/CD56^dim ratios
| Normal NK Cell Range | Reference Values |
|---|---|
| Absolute NK Count | 90–600 cells/µL |
| NK % of Lymphocytes | 5–20% |
NK cells are increasingly targeted in cancer therapy:
✅ CAR-NK Therapy: Genetically engineered NK cells for tumor targeting
✅ Monoclonal Antibody Therapies (e.g., Rituximab, Daratumumab): Enhance NK-mediated antibody-dependent cellular cytotoxicity (ADCC)
✅ IL-15 & Checkpoint Inhibitors: Boost NK cell cytotoxic function in cancers
✅ CD16/CD56 markers define NK cell function and subsets
✅ Low NK cells: Seen in immunodeficiency, chronic infections, cancer
✅ High NK cells: Common in acute infections, inflammation, NK cell malignancies
✅ NK cells play a major role in cancer immunotherapy (CAR-NK, monoclonal antibodies)
₹3,999.00 Original price was: ₹3,999.00.₹2,899.00Current price is: ₹2,899.00.